Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia

Glycogen synthase kinase-3 (GSK3) inhibitors induce differentiation and growth inhibition of acute myeloid leukemia (AML) cells. Our pre-clinical studies showed GSK3 inhibition leads to sensitization of AML cells to tretinoin-mediated differentiation. We conducted a phase I trial of lithium, a GSK3...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Masumi, Stefan, Tammy, Stetson, Lindsay, Ignatz-Hoover, James J., Tomlinson, Benjamin, Creger, Richard J., Cooper, Brenda, Lazarus, Hillard M., de Lima, Marcos, Wald, David N., Caimi, Paolo F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076174/
https://www.ncbi.nlm.nih.gov/pubmed/32211336
http://dx.doi.org/10.3389/fonc.2020.00327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076174/
https://www.ncbi.nlm.nih.gov/pubmed/32211336
http://dx.doi.org/10.3389/fonc.2020.00327

Ejemplares similares